IL1RAP BINDING PROTEINS

The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL1RAP 0 antagoni...

Full description

Saved in:
Bibliographic Details
Main Authors YANG Teddy, KUMAR Sanjay, REN Fang, YING Hua, EMERY John G, GONG Shiyong, FEI Qi
Format Patent
LanguageEnglish
Spanish
Published 14.06.2022
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease. La presente invención se refiere en general a los anticuerpos en el tratamiento de enfermedades humanas y la reducción de eventos adversos relacionados con ellas. Más específicamente, la presente invención se refiere al uso de proteínas de unión a IL1RAP (proteína accesoria del receptor de interleucina 1) (incluyendo anticuerpos antagonistas de IL1RAP) y su uso como tratamiento y prevención de enfermedades humanas.
Bibliography:Application Number: MX2021015651